CN1209137C - Chinese herbal medicine for treating hemopathy - Google Patents
Chinese herbal medicine for treating hemopathy Download PDFInfo
- Publication number
- CN1209137C CN1209137C CN 02151139 CN02151139A CN1209137C CN 1209137 C CN1209137 C CN 1209137C CN 02151139 CN02151139 CN 02151139 CN 02151139 A CN02151139 A CN 02151139A CN 1209137 C CN1209137 C CN 1209137C
- Authority
- CN
- China
- Prior art keywords
- radix
- root
- gram
- thousand
- crude drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to a Chinese herbal medicine for treating various hemopathy, such as aplastic anemia, anemia, thrombocytopenia, myelosis type hemocytopenia, leukaemia, etc. The Chinese herbal medicine comprises a decoction preparation and a power preparation, wherein the decoction preparation comprises the raw medicinal materials of 12 to 18g of Chinese angelica root, 12 to 18g of astragalus root, 12 to 18g of peony, 9 to 15g of Chinese yam, 14 to 26g of solomonseal rhizome, 7 to 13g of licorice root, 12 to 18g of white atractylodes rhizome, 14 to 26g of honeysuckle stem, 14 to 26g of manyflower glorybower root, 24 to 36g of agrimony, 24 to 36g of elaeagnus pungens root, 12 to 18g of common sage herb and 12 to 18g of dandelion; the power preparation comprises the raw medicinal materials of 0.7 to 1.3g of geum Japonica, 0.2 to 0.4g of snakegourd fruit, 0.1 to 0.3g of notoginseng, 0.3 to 0.7g of cucumber root, 1.2 to 1.8g of common camptotheca leaf and 0.3 to 0.7g of hemsley rockvine root. The formula of the present invention is reasonable, and the Chinese herbal medicine has the efficacy of supporting healthy energy to eliminate evil, benefiting Yin and Yang, promoting vital energy and blood formation, enhancing the phagocytic function of macrophage, relieving microcirculatory injury of marrow, inhibiting pathologic cell growth, enhancing the immunity of an organism, etc. The Chinese herbal medicine has the characteristics of stable therapeutic effect, etc. As proved by clinical experiments, the total effective rate of the therapeutic effect of the present invention relates to 98%, and the cure rate is more than 90%.
Description
Technical field
The present invention relates to multiple hemopathic Chinese herb medicines such as the various aplastic anemia of a kind of treatment, anemia, thrombocytopenia, myeloproliferative pancytopenia, leukemia.
Background technology
Leukemia is commonly called as " leukemia ", is harm people ' s health, particularly teenager and the higher a kind of hemopoietic system malignant disease of child's sickness rate.Most of leukemia people adopts the doctor trained in Western medicine chemotherapy.Though this therapy can be killed a large amount of outgrowth juvenile cells, lack necessary security and effectiveness.When killing the hypertrophy juvenile cell because of the chemotherapy medication, also can kill many normal cells and leukocyte, patient's immunity of organisms is reduced, might cause patient's early infection and cause other complication, and chemotherapy failure mainly to be chemotherapy phase endogenous cause of ill infect and hemorrhagely cause early stage death, or leukaemia's drug resistance and to no effect.Chinese medicine can remedy the deficiency that the doctor trained in Western medicine chemotherapy is not distinguished between the enemy and ourselves and killed simply, can solve again the chemical sproof problem of chemotherapeutic.Through consulting, Chinese patent literature application number 92103647.7 discloses " a kind of compound method for the treatment of leukemia Chinese medicine ", it replaces chemotherapy with Chinese medicine, both avoided because the misery that chemotherapy is brought to patient and the toxic and side effects of Western medicine, again can vital base and primordial QI consolidating, QI and blood regulating, mitigate the disease, prolong leukaemic's life cycle, but said composition mainly adapts to leukemia, holding concurrently has auxiliary curative effect to aplastic anemia, and do not see and can also treat other hemopathic report, and high not enough to leukemic curative effect.
Summary of the invention
The technical issues that need to address of the present invention are to provide a kind of adaptation multiple hematopathy, the herbal composite of better efficacy.
Prescription of the present invention is: the decoct crude drug: Radix Angelicae Sinensis 12～18g, the Radix Astragali 12～18g, Radix Paeoniae 12～18g, Rhizoma Dioscoreae 9～15g, Rhizoma Polygonati 14～26g, Radix Glycyrrhizae 7～13g, the Rhizoma Atractylodis Macrocephalae 12～18g, Caulis Lonicerae 14～26g, Radix Clerodenri Cyrtophylli 14～26g, Agrimony 24～36g, Radix Elaeagni 24～36g, Herba Salviae Plebeiae 12～18g, Herba Taraxaci 12～18g; Powder crude drug: Japanese avens 0.7～1.3g, stone Bufo siccus 0.2～0.4g, Radix Notoginseng 0.1～0.3g, Radix Cucumidis sativi 0.3～0.7g, Folium Camptothecae Acuminatae 1.2～1.8g, Radix Apioris Fortunei (Radix Lespedezae Buergeri) 0.3～0.7g; Can also add in the above decoct prescription: Ramulus Cinnamomi 4～8g, Rhizoma Atractylodis 4～8g, Radix Salviae Miltiorrhizae 9～15g, Rhizoma Polygoni Cuspidati 7～13g are in harmonious proportion.For acute lymphoblastic leukemia, can also add Herba Houttuyniae 12～18g, Radix berchemiae lineatae 12～18g, Fructus Forsythiae 9～15g, Radix Semiaquilegiae 9～15g in the above decoct.Decoct in the present invention prescription can conventional decoction, also can make various dosage forms such as electuary, water preparation takes, the part component causes the loss of active component because of consumption is little in the decoction process, and control dosage accurately, powder in the prescription generally after the meal one hour with the single clothes of conventional powder or capsule form, every day two to three times; Decoction ante cibum one after each meal all can, dosage is every day two to three times.
Use during the Drug therapy of the present invention, note rule of life, keep spirit happy, can carry out suitable physical exertion, but too not worry about fatigue, and, prevent flu away from sexual life; Anemia person should not transfuse blood more, and serious anemia person can fail a small amount of blood with emergent, should prolong interval but transfuse blood, in order to avoid the patient produces dependency to blood transfusion.
Period in a medicine keeps vegetarian diet substantially.Can eat vegetable (comprising Radix Raphani, Bulbus Allii, Lentinus Edodes etc.), diet wine, chicken, egg, seafood, fried, pickle, mouldy food, pig head meat, Sanguis sus domestica, high protein one class (Trionyx sinensis Wiegmann, Monopterus albus (Zuiew), Misgurni anguillicaudati, shrimp, eel), suitably edible duck, Ovum Anas domestica, Carnis Sus domestica, fresh fresh-water fishes (Ctenopharyngodon idellus, Carassius auratus etc.).
The inventor thinks, the various disease of hematology, its old complaint source in kidney, pathological changes in liver spleen, clinical manifestation at blood and lung, and leukemia has a general character: be exactly that clinical manifestation is that kidney yin is lost, the phase hyperactivity of fire, accumulate that poison is dark, the impairment of YIN hematozemia, dash, appoint, superintend and direct the imbalance of three arteries and veins.Therefore in therapeutic process, answer nourishing the liver and kidney, benefiting QI and nourishing blood, heat-clearing and toxic substances removing, be equipped with complementary therapies such as diet, physical training again.The inventor think leukemia and ancient times consumptive disease, chronic consumptive disease similar, but medication can not be adopted ancient prescription merely, must innovation.The present invention take determination of treatment based on pathogenesis obtained through differentiation of symptoms and signs and integrality to regulate to combine method, treating both the principal and secondary aspects of a disease, from QI and blood, internal organs, many-sided medical treatment such as negative and positive, the yin nourishing YANG hyperactivity suppressing, separate and accumulate poison, reducing the minister-fire, conditioning is dashed, appoint, superintend and direct, the benefit kidney and replenishing marrow, training amended copy source, with blood stasis dispelling, purify the blood, set upright, a series of drug regimens detoxify, control leukaemia's growth effectively, make it gradually to transform and decompose, kill the part leukaemia simultaneously, thereby improve the stem cell (CFU-S) of hemopoietic damage, grain is the quantity of CFU-GM (CFU-G) and CFU-E (CFU-E), promote the human body metabolism, toxin is excreted.The reasonable compatibility of all medicines in the above-mentioned prescription, have the hematopoieticmicroenviron-ment of improvement and regulate immunization, can remove brain stasis of blood resistance and help the regeneration of hemocyte, can make hemopoietic function, hemopoietic functional rehabilitation normal effectively, increase body resistance against diseases, control leukocytic unlimited increase or minimizing, remove hematopoietic disorders, reach the purpose of treatment on the basis of physiologic immunity that improves hematopathy patients such as leukemia and regulatory function, clinical practice has also proved this point.
The present invention fills a prescription rationally, can correspondingly reduce the treatment cost, it has the effect of strengthening vital QI to eliminate pathogenic factors, tonifying YIN sun, angry blood simultaneously, can improve the phagocytic function of macrophage, alleviate the bone marrow microcirculatory injury, remove hematopoietic disorders, promote normal plasma cell to grow, suppress the pathological cells growth, enhancing human body immunity power, characteristics such as stable curative effect.Clinical trial certificate, the total effective rate of curative effect of the present invention are about 98%, and cure rate is more than 90%.
The specific embodiment
Below by embodiment, technical scheme of the present invention is described in further detail.
Embodiment 1, is to be made by following raw materials by weight proportions:
Decoct crude drug: Radix Angelicae Sinensis 15g, Radix Astragali 15g, Radix Paeoniae 15g, Rhizoma Dioscoreae 12g, Rhizoma Polygonati 20g, Radix Glycyrrhizae 10g, Rhizoma Atractylodis Macrocephalae 15g, Caulis Lonicerae 20g, Radix Clerodenri Cyrtophylli 20g, Agrimony 30g, Radix Elaeagni 30g, Herba Salviae Plebeiae 15g, Herba Taraxaci 15g; Powder crude drug: Japanese avens 1g, stone Bufo siccus 0.3g Radix Notoginseng 0.2g, Radix Cucumidis sativi 0.5g, Folium Camptothecae Acuminatae 1.5g, Radix Apioris Fortunei (Radix Lespedezae Buergeri) 0.5g.
Embodiment 2, are to be made by following raw materials by weight proportions:
Decoct crude drug: Radix Angelicae Sinensis 12g, Radix Astragali 18g, Radix Paeoniae 12g, Rhizoma Dioscoreae 9g, Rhizoma Polygonati 26g, Radix Glycyrrhizae 13g, Rhizoma Atractylodis Macrocephalae 12g, Caulis Lonicerae 26g, Radix Clerodenri Cyrtophylli 14g, Agrimony 24g, Radix Elaeagni 34g, Herba Salviae Plebeiae 12g, Herba Taraxaci 18g; Powder crude drug: Japanese avens 0.7g, stone Bufo siccus 0.4g Radix Notoginseng 0.3g, Radix Cucumidis sativi 0.7g, Folium Camptothecae Acuminatae 1.8g, Radix Apioris Fortunei (Radix Lespedezae Buergeri) 0.3g.
Embodiment 3, are to be made by following raw materials by weight proportions:
Decoct crude drug: Radix Angelicae Sinensis 18g, Radix Astragali 12g, Radix Paeoniae 18g, Rhizoma Dioscoreae 15g, Rhizoma Polygonati 14g, Radix Glycyrrhizae 7g, Rhizoma Atractylodis Macrocephalae 18g, Caulis Lonicerae 14g, Radix Clerodenri Cyrtophylli 26g, Agrimony 36g, Radix Elaeagni 26g, Herba Salviae Plebeiae 18g, Herba Taraxaci 12g; Powder crude drug: Japanese avens 1.3g, stone Bufo siccus 0.2g Radix Notoginseng 0.1g, Radix Cucumidis sativi 0.3g, Folium Camptothecae Acuminatae 1.2g, Radix Apioris Fortunei (Radix Lespedezae Buergeri) 0.7g.
Embodiment 4, are to be made by following raw materials by weight proportions:
Decoct crude drug: Radix Angelicae Sinensis 15g, Radix Astragali 15g, Radix Paeoniae 15g, Rhizoma Dioscoreae 12g, Rhizoma Polygonati 20g, Radix Glycyrrhizae 10g, Rhizoma Atractylodis Macrocephalae 15g, Caulis Lonicerae 20g, Radix Clerodenri Cyrtophylli 20g, Agrimony 30g, Radix Elaeagni 30g, Herba Salviae Plebeiae 15g, Herba Taraxaci 15g, Ramulus Cinnamomi 6g, Rhizoma Atractylodis 6g, Radix Salviae Miltiorrhizae 12g, Rhizoma Polygoni Cuspidati 10g; Powder crude drug: Japanese avens 1g, stone Bufo siccus 0.3g, Radix Notoginseng 0.2g, Radix Cucumidis sativi 0.5g, Folium Camptothecae Acuminatae 1.5g, Radix Apioris Fortunei (Radix Lespedezae Buergeri) 0.5g
Embodiment 5, are to be made by following raw materials by weight proportions:
Decoct crude drug: Radix Angelicae Sinensis 12g, Radix Astragali 18g, Radix Paeoniae 12g, Rhizoma Dioscoreae 9g, Rhizoma Polygonati 26g, Radix Glycyrrhizae 13g, Rhizoma Atractylodis Macrocephalae 12g, Caulis Lonicerae 26g, Radix Clerodenri Cyrtophylli 14g, Agrimony 24g, Radix Elaeagni 34g, Herba Salviae Plebeiae 12g, Herba Taraxaci 18g, Ramulus Cinnamomi 4g, Rhizoma Atractylodis 8g, Radix Salviae Miltiorrhizae 9g, Rhizoma Polygoni Cuspidati 13g; Powder crude drug: Japanese avens 0.7g, stone Bufo siccus 0.4g Radix Notoginseng 0.3g, Radix Cucumidis sativi 0.7g, Folium Camptothecae Acuminatae 1.8g, Radix Apioris Fortunei (Radix Lespedezae Buergeri) 0.3g.
Embodiment 6, are to be made by following raw materials by weight proportions:
Decoct crude drug: Radix Angelicae Sinensis 18g, Radix Astragali 12g, Radix Paeoniae 18g, Rhizoma Dioscoreae 15g, Rhizoma Polygonati 14g, Radix Glycyrrhizae 7g, Rhizoma Atractylodis Macrocephalae 18g, Caulis Lonicerae 14g, Radix Clerodenri Cyrtophylli 26g, Agrimony 36g, Radix Elaeagni 26g, Herba Salviae Plebeiae 18g, Herba Taraxaci 12g, Ramulus Cinnamomi 8g, Rhizoma Atractylodis 4g, Radix Salviae Miltiorrhizae 15g, Rhizoma Polygoni Cuspidati 7g; Powder crude drug: Japanese avens 1.3g, stone Bufo siccus 0.2g Radix Notoginseng 0.1g, Radix Cucumidis sativi 0.3g, Folium Camptothecae Acuminatae 1.2g, Radix Apioris Fortunei (Radix Lespedezae Buergeri) 0.7g.
Be mixed with decoct and powder respectively by above-mentioned prescription and dosage, clinography shows that the present invention has comparatively ideal curative effect.
Table 1,12 routine leukaemics treat record
| Case | Disease | Before taking medicine | After taking medicine |
| Case one grandson *Woman 35 years old | Begin to take medicine after acute nonlymphocytic leukemia (M3) chemotherapy three times | Withdraw after 1 year, now all are normal, cure. | |
| Case two horses *Woman 43 years old | Begin to take medicine after acute nonlymphocytic leukemia (M5b) chemotherapy three times | Withdraw after 1 year, now all are normal, cure. | |
| Case three is old *Woman 20 years old | Begin to take medicine after acute nonlymphocytic leukemia (M3) chemotherapy 5 times | Body weight 30Kg, WBC700, HGb3 gram, PLT9000 | Withdrawal WBC5800 after 10 months, the HGb11.5 gram, PLT10.8 ten thousand now can take part in the work, all are normal, cure. |
| Case four is contained *Man 17 years old | Begin to take medicine after acute nonlymphocytic leukemia (M3) chemotherapy three times | WBC3000, the HGb10 gram, PLT6 ten thousand | Withdrawal WBC4100 after 10 months, the HGb12.9 gram, PLT10.8 ten thousand has cured. |
| Case five grandsons *Woman 38 years old | Acute nonlymphocytic leukemia (M3) chemotherapy begins to take medicine after once | WBC800, the HGb3.3 gram, PLT4.9 ten thousand | Withdrawal WBC4800 after 10 months, the HGb12.3 gram, PLT13 ten thousand is existing, and all are normal, cure. |
| Case six horses *Woman 33 years old | Begin to take medicine after acute nonlymphocytic leukemia (M2b) chemotherapy three times | WBC1400, the HGb5.9 gram, PLT1.8 ten thousand | Withdrawal WBC6000 after 8 months, the HGb11.2 gram, PLT12 ten thousand is existing, and all are normal, cure |
| Case seven Lee *Woman 6 years old | Begin to take medicine after twice of acute lymphoblastic leukemia (L2) chemotherapy | Withdrawal after 1 year, now all are normal, cure. | |
| Case eight reeds *Man 28 years old | Begin to take medicine after acute lymphoblastic leukemia (L2) chemotherapy three times | Existing all are normal in withdrawal after 10 months, cure. | |
| Case nine clocks *Man 5 years old | Acute lymphoblastic leukemia (L2) chemotherapy begins to take medicine after once | Existing all are normal in withdrawal after 1 year, cure. | |
| Case ten is old *Woman 42 years old | Begin to take medicine after acute lymphoblastic leukemia (M2) chemotherapy | WBC2000, the HGb8.2 gram, PLT5 ten thousand | WBC3900 after taking medicine 40 days, the HGb10.2 gram, PLT12.5 ten thousand |
| 11 weeks of case *Man 43 years old | Begin to take medicine after acute lymphoblastic leukemia (M2) chemotherapy | WBC400, the HGb4.6 gram, PLT1.3 ten thousand | WBC1200 after taking medicine 10 days, the HGb6 gram, PLT3 ten thousand |
| Case 12 Bearss *Woman 16 years old | Begin to take medicine after acute lymphoblastic leukemia (L2) chemotherapy | WBC2000, the HGb5 gram, PLT1.8 ten thousand | WBC5000 after taking medicine 10 days, the HGb8 gram, PLT7.8 ten thousand |
The full cell of table 2,11 routine aplastic anemia and 1 routine myeloproliferative reduces sick treatment record
| Case | Disease | Before taking medicine | After taking medicine |
| Case one China *Woman 35 years old | The full cell of myeloproliferative reduces sick (MDS) chemotherapy and begins to take medicine for three times | WBC2000, the HGb7 gram, PLT5 ten thousand | Withdraw after 1 year, now all are normal, cure. |
| Case two Xu *Man 15 years old | Aplastic anemia | WBC4000, the HGb2.3 gram, PLT1.9 ten thousand (5/day of prednisones, the injection in per 15 days of third ball are once) | After taking medicine 3 months, hormone drug is withdrawn, WBC5100, and the HGb5.5 gram, PLT3 ten thousand has cured. |
| Case three fur coats *Woman 28 years old | Aplastic anemia | WBC2300, HGb4.3 gram, PLT1.3 ten thousand (6/day of Cyclosporin As are pacified 2/day of male sheets) | After taking medicine 2 months, hormone drug is withdrawn, WBC3800, and the HGb7.4 gram, PLT4.8 ten thousand |
| Case four Shes *Man 12 years old | Aplastic anemia | WBC5000, the HGb1.2 gram, PLT9000, nose. gingival hemorrhage, whole body have petechia blue piece. | Bleeding disappears after one month, WBC1500, the HGb3.8 gram, PLT4 ten thousand, drug withdrawal after 1 year, WBC7000, HGb12 gram, PLT15 ten thousand, cure. |
| Case five Yu *Man 5 years old, | Aplastic anemia | WBC2000, the HGb3.1 gram, PLT3 ten thousand, | Withdrawal after 10 months, WBC7600, the HGb12.5 gram, PLT18 ten thousand, cure. |
| Case six Shen *Man 51 years old | Aplastic anemia | WBC1700, the HGb6 gram, PLT1.1 ten thousand | WBC2000 after taking medicine 1 month, the HGb6.5 gram, PLT3 ten thousand |
| Case seven Jiang *Woman 47 years old | Aplastic anemia | WBC3100, the HGb7.7 gram, PLT22.6 ten thousand | WBC4500 after taking medicine 10 days, the HGb9 gram, PLT5.6 ten thousand |
| Case eight Shen *Woman 38 years old | Aplastic anemia | WBC1400, the HGb3.4 gram, PLT4000 (third ball is injected once every day, and strong send 1/day) | WBC3800 after taking medicine 20 days, HGb3.8 gram, PLT8000 |
| Case nine grandsons *Man 50 years old | Aplastic anemia | WBC2700, the HGb15.3 gram, PLT7.8 ten thousand | WBC3800 after taking medicine one month, the HGb14.5 gram, PLT8.5 ten thousand |
| Case ten Xu *Woman 23 years old | Aplastic anemia | WBC1500, HGb2.2 gram, PLT5000 | Wbc2000 after taking medicine 1 month, the Hgb3 gram, PLT1 ten thousand |
| Case 11 models *Man 38 years old | Aplastic anemia | WBC2300, HGb7.7 gram, PLT9000 | After taking medicine 3 months, WBC2700, the HGb9 gram, PLT1.4 ten thousand. |
3, the sick treatment of 8 routine thrombocytopenia record
| Case | Disease | Before taking medicine | After taking medicine |
| Case one sieve *Woman 7 years old | The special property sent out thrombocytopenia disease | WBC1.65 ten thousand, the HGb12.7 gram, and PLT3.8 ten thousand | WBC7200 after taking medicine 5 months, the HGb12.1 gram, PLT12.5 ten thousand |
| Case two grandsons *Man 23 years old | The sick medical history of the special property sent out thrombocytopenia 12 years | WBC1400, HGb11 gram, PLT4000 (9/day of prednisones) | WBC7200 after taking medicine six months, the HGb13.2 gram, PLT18 ten thousand, cure. |
| Case three is heard *Man 7 years old | The special property sent out thrombocytopenia disease | WBC2 ten thousand, HGb14.4 gram, PLT7000 (7/day of prednisones) | WBC6800 after taking medicine 4 months, the HGb15 gram, PLT17 ten thousand, cure |
| Case four Feng *Woman 39 years old | Thrombocytopenia (ITP) | WBC5000, the HGb13.3 gram, PLT5.1 ten thousand | WBC4900 after taking medicine one month, the HGb13.2 gram, PLT7.1 ten thousand |
| Case five poplars *Woman 31 years old | Thrombocytopenia medical history 2 years | WBC1.2 ten thousand, HGb14.7 gram, PLT7 ten thousand (6/day of prednisones) | After taking medicine 4 months, (the prednisone medicine is withdrawn) WBC6100, the HGb14.4 gram, PLT10.3 ten thousand, cure. |
| Case six height *Man 11 years old, | Thrombocytopenia | WBC1.37 ten thousand, the HGb12.6 gram, and PLT1 ten thousand, take prednisone simultaneously | After taking medicine 3 months, the prednisone medicine is withdrawn, WBC7000, the HGb12.5 gram, PLT8 ten thousand, cure. |
| Case seven Guo *Man 2 years old | The special property sent out thrombocytopenia | WBC1.36 ten thousand, the HGb11.4 gram, and PLT5.3 ten thousand, 3/day of prednisones | After taking medicine 3 months, prednisone is withdrawn, WBC8600, the HGb13.6 gram, PLT16.8 ten thousand, cure. |
| Case eight once *Man 6 years old | The constitutional thrombocytopenia | WBC6400, HGb10.4 gram, PLT7000,1.5/day of prednisones | Prednisone is 0.5/day after taking medicine 1 month, WBC6700, HGb11.5 gram, PLT9000 |
The total effective rate of total effects of the present invention is about 98%, and cure rate is more than 90%.
Above-mentioned three tables are data from the wherein part of total case.
Embodiment 7, are to be made by following raw materials by weight proportions:
Decoct crude drug: Radix Angelicae Sinensis 15g, Radix Astragali 15g, Radix Paeoniae 15g, Rhizoma Dioscoreae 12g, Rhizoma Polygonati 20g, Radix Glycyrrhizae 10g, Rhizoma Atractylodis Macrocephalae 15g, Caulis Lonicerae 20g, Radix Clerodenri Cyrtophylli 20g, Agrimony 30g, Radix Elaeagni 30g, Herba Salviae Plebeiae 15g, Herba Taraxaci 15g, Ramulus Cinnamomi 6g, Rhizoma Atractylodis 6g, Radix Salviae Miltiorrhizae 12g, Rhizoma Polygoni Cuspidati 10g, Herba Houttuyniae 15g, Radix berchemiae lineatae 15g, Fructus Forsythiae 12g, Radix Semiaquilegiae 12g; Powder crude drug: Japanese avens 1g, stone Bufo siccus 0.3g, Radix Notoginseng 0.2g, Radix Cucumidis sativi 0.5g, Folium Camptothecae Acuminatae 1.5g, Radix Apioris Fortunei (Radix Lespedezae Buergeri) 0.5g.
Embodiment 8, are to be made by following raw materials by weight proportions:
Decoct crude drug: Radix Angelicae Sinensis 12g, Radix Astragali 18g, Radix Paeoniae 12g, Rhizoma Dioscoreae 9g, Rhizoma Polygonati 26g, Radix Glycyrrhizae 13g, Rhizoma Atractylodis Macrocephalae 12g, Caulis Lonicerae 26g, Radix Clerodenri Cyrtophylli 14g, Agrimony 24g, Radix Elaeagni 34g, Herba Salviae Plebeiae 12g, Herba Taraxaci 18g, Ramulus Cinnamomi 4g, Rhizoma Atractylodis 8g, Radix Salviae Miltiorrhizae 9g, Rhizoma Polygoni Cuspidati 13g, Herba Houttuyniae 12g, Radix berchemiae lineatae 18g, Fructus Forsythiae 9g, Radix Semiaquilegiae 15g; Powder crude drug: Japanese avens 0.7g, stone Bufo siccus 0.4g, Radix Notoginseng 0.3g, Radix Cucumidis sativi 0.7g, Folium Camptothecae Acuminatae 1.8g, Radix Apioris Fortunei (Radix Lespedezae Buergeri) 0.3g.
Embodiment 9, are to be made by following raw materials by weight proportions:
Decoct crude drug: Radix Angelicae Sinensis 18g, Radix Astragali 12g, Radix Paeoniae 18g, Rhizoma Dioscoreae 15g, Rhizoma Polygonati 14g, Radix Glycyrrhizae 7g, Rhizoma Atractylodis Macrocephalae 18g, Caulis Lonicerae 14g, Radix Clerodenri Cyrtophylli 26g, Agrimony 36g, Radix Elaeagni 26g, Herba Salviae Plebeiae 18g, Herba Taraxaci 12g, Ramulus Cinnamomi 8g, Rhizoma Atractylodis 4g, Radix Salviae Miltiorrhizae 15g, Rhizoma Polygoni Cuspidati 7g, Herba Houttuyniae 18g, Radix berchemiae lineatae 12g, Fructus Forsythiae 15g, Radix Semiaquilegiae 9g; Powder crude drug: Japanese avens 1.3g, stone Bufo siccus 0.2g, Radix Notoginseng 0.1g, Radix Cucumidis sativi 0.3g, Folium Camptothecae Acuminatae 1.2g, Radix Apioris Fortunei (Radix Lespedezae Buergeri) 0.7g.
Above-mentioned three example prescriptions are specially adapted to acute lymphoblastic leukemia, are mixed with decoct and powder respectively by described dosage, and clinography shows that the present invention has comparatively ideal curative effect.
Claims (3)
1, the multiple hemopathic herbal composite of a kind of treatment is characterized in that it is made by following bulk drugs:
Decoct crude drug: Radix Angelicae Sinensis 12～18g Radix Astragali 12～18g Radix Paeoniae 12～18g Rhizoma Dioscoreae 9～15g
Rhizoma Polygonati 14～26g Radix Glycyrrhizae 7～13g Rhizoma Atractylodis Macrocephalae 12～18g Caulis Lonicerae 14～26g Radix Clerodenri Cyrtophylli 14～26g
Agrimony 24～36g Radix Elaeagni 24～36g Herba Salviae Plebeiae 12～18g Herba Taraxaci 12～18g;
Powder crude drug: Japanese avens 0.7～1.3g stone Bufo siccus 0.2～0.4g Radix Notoginseng 0.1～0.3g
Radix Cucumidis sativi 0.3～0.7g Folium Camptothecae Acuminatae 1.2～1.8g Radix Apioris Fortunei (Radix Lespedezae Buergeri) 0.3～0.7g.
2, the multiple hemopathic herbal composite of treatment according to claim 1 is characterized in that also having in the described decoct crude drug: Ramulus Cinnamomi 4～8g Rhizoma Atractylodis 4～8g Radix Salviae Miltiorrhizae 9～15g Rhizoma Polygoni Cuspidati 7～13g.
3, the multiple hemopathic herbal composite of treatment according to claim 2 is characterized in that also having in described decoct crude drug: Herba Houttuyniae 12～18g Radix berchemiae lineatae 12～18g Fructus Forsythiae 9～15g Radix Semiaquilegiae 9～15g.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 02151139 CN1209137C (en) | 2002-12-02 | 2002-12-02 | Chinese herbal medicine for treating hemopathy |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 02151139 CN1209137C (en) | 2002-12-02 | 2002-12-02 | Chinese herbal medicine for treating hemopathy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1440769A CN1440769A (en) | 2003-09-10 |
| CN1209137C true CN1209137C (en) | 2005-07-06 |
Family
ID=27768604
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 02151139 Expired - Fee Related CN1209137C (en) | 2002-12-02 | 2002-12-02 | Chinese herbal medicine for treating hemopathy |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1209137C (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101147511B (en) * | 2006-09-20 | 2010-06-16 | 杨光孝 | Pseudo-ginseng flower health preserving tea |
| CN103127315A (en) * | 2013-02-25 | 2013-06-05 | 胡馨尹 | Hemsley rockvine root tuber used for treating lupus erythematosus |
| CN103784797A (en) * | 2014-01-26 | 2014-05-14 | 宋志芳 | Traditional Chinese medicine for treating chronic lymphocytic leukemia |
| JP6732967B2 (en) * | 2016-03-08 | 2020-07-29 | チェン ラブ アンド カンパニー リミテッド ライアビリティ カンパニー | Herbal formulation for increasing pH level of human body from acidic to more alkaline |
| CN110051780B (en) * | 2019-04-17 | 2021-05-25 | 昆明邦宇制药有限公司 | Composition with function of enhancing immunity and preparation method thereof |
-
2002
- 2002-12-02 CN CN 02151139 patent/CN1209137C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1440769A (en) | 2003-09-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101461921B (en) | Medicinal composition for treating gynecopathy | |
| WO2008115583A1 (en) | Herbal treatments | |
| CN1305515C (en) | Chinese medicinal powder and decoction composition for treating cancer | |
| CN1209137C (en) | Chinese herbal medicine for treating hemopathy | |
| CN102631518B (en) | New medicament for treating leukemia | |
| CN101455764B (en) | Traditional Chinese medicine for treating zoster | |
| CN105994867A (en) | Chocolate with effect of improving immunity and preparation method thereof | |
| CN102973758A (en) | Traditional Chinese medicine composition for treating depression | |
| CN1146437C (en) | Medicine for treating hematopathy | |
| CN1883642A (en) | Medicine for treating mammary glands hyperplasia | |
| CN1073861C (en) | External use medicinal bag for treating acute and chronic gastritis and cholecystitis, and preparing method thereof | |
| CN1162172C (en) | Baixue-Genzhi-Changshoubao-Chinese medicine for treating leukemia and concurrently treating aplastic anemia | |
| CN1294980C (en) | Medicine for treating liver disease | |
| CN101199667A (en) | Chinese medicine for treating leukemia, aplastic anemia | |
| CN1843492A (en) | Traditional Chinese medicine preparation for treating mammary gland hyperplasia | |
| CN104435545A (en) | Traditional Chinese medicine preparation for treating leucopenia caused by benzene poisoning | |
| CN103877509B (en) | A kind of medicine and its preparation method treating leukemia | |
| CN1113664C (en) | Prepn. of hematopoietic tortoise-deer capsule | |
| CN101804159B (en) | Traditional Chinese medicine preparation for treating aplastic anemia | |
| CN101884747B (en) | Traditional Chinese medicine for treating chronic nephritis | |
| CN1628828B (en) | Chinese medicine for preventing and resisting cancer | |
| CN105687715B (en) | Traditional Chinese medicine composition for treating chronic benzene poisoning thrombopenia and leukopenia | |
| CN105168613A (en) | Traditional Chinese medicine preparation for treating leukemia at emergency stage | |
| CN1415363A (en) | Biochemical medicament of araliaceae plant and its preparation method | |
| CN103169899B (en) | Drug for treating hydrops articuli |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: LINAN XU JIN PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: GUO WUJIN Effective date: 20090619 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20090619 Address after: Hangzhou City, Zhejiang province Jianggan District five road 1 zip code: 310016 Patentee after: Ling'an Xu Jin Pharmaceutical Co., Ltd. Address before: Zhejiang province Hangzhou Fuyang Zi village Shoujiang zip code: 311422 Co-patentee before: Chai Ruifen Patentee before: Guo Wu Jin |
|
| ASS | Succession or assignment of patent right |
Owner name: CHAI RUIFEN Owner name: GUO WUJIN Free format text: FORMER OWNER: LIN AN XUJIN MEDICAL CO., LTD. Effective date: 20100622 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 310016 NO.1, WUAN ROAD, JIANGGAN DISTRICT, HANGZHOU CITY, ZHEJIANG PROVINCETO: 311422 ZISHU VILLAGE, SHOUJIANG TOWN, FUYANG, HANGZHOU CITY, ZHEJIANG PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20100622 Address after: 311422 Zhejiang province Hangzhou Fuyang Shoujiang Zi Village Co-patentee after: Chai Ruifen Patentee after: Guo Wujin Address before: Hangzhou City, Zhejiang province 310016 Jianggan District five road 1 Patentee before: Ling'an Xu Jin Pharmaceutical Co., Ltd. |
|
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20050706 Termination date: 20101202 |